Renal Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Molecular Biology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes.
• The role of Angiopoietin-like 4 (ANGPTL4) in DKD pathogenesis is not well understood.
• ANGPTL4 is implicated in lipoprotein metabolism and has diverse biological effects.

Purpose of the Study:

• To investigate the role of podocyte- and tubule-specific ANGPTL4 in diabetic kidney fibrosis.
• To elucidate the molecular mechanisms by which ANGPTL4 contributes to DKD.
• To evaluate the therapeutic potential of inhibiting ANGPTL4 in DKD.

Main Methods:

• Utilized ANGPTL4 mutant mice to assess its role in diabetes-induced kidney fibrosis.
• Analyzed molecular pathways including inflammation, epithelial-mesenchymal transition (EMT), and mitochondrial function.
• Investigated the interaction of ANGPTL4 with Integrin β1 in kidney cells.
• Tested a targeted pharmacologic therapy inhibiting kidney ANGPTL4 gene expression.

Main Results:

• Podocyte- and tubule-specific ANGPTL4 are crucial fibrogenic factors in diabetic kidneys.
• ANGPTL4 deficiency protected mice from diabetes-induced kidney fibrosis.
• Protection was associated with reduced inflammation, EMT, and mitochondrial damage, alongside increased fatty acid oxidation.
• ANGPTL4 interacts with Integrin β1, influencing downstream signaling pathways.
• Targeted inhibition of kidney ANGPTL4 ameliorated proteinuria and fibrosis in diabetic kidneys.

Conclusions:

• Podocyte- and tubule-derived ANGPTL4 plays a significant fibrogenic role in diabetic kidney disease.
• ANGPTL4 inhibition represents a promising therapeutic strategy for DKD.
• Understanding ANGPTL4's molecular interactions provides insights into DKD pathogenesis.